PMID- 28236571 OWN - NLM STAT- MEDLINE DCOM- 20180606 LR - 20180606 IS - 1878-1780 (Electronic) IS - 1262-3636 (Linking) VI - 43 IP - 4 DP - 2017 Sep TI - Multicentre randomized controlled trial with sensor-augmented pump vs multiple daily injections in hospitalized patients with type 2 diabetes in China: Time to reach target glucose. PG - 359-363 LID - S1262-3636(17)30001-0 [pii] LID - 10.1016/j.diabet.2016.12.009 [doi] AB - AIM: Sensor-augmented pump (SAP) technology, which combines continuous subcutaneous insulin infusion (CSII) and real-time continuous glucose monitoring (RT-CGM), has been available for several years in China. In this study, the time required to reach predefined glycaemic targets with SAP vs multiple daily injection (MDI) therapy was compared in hospitalized patients with type 2 diabetes mellitus (T2DM). METHODS: Adults (aged 18-65 years) with T2DM treated with insulin and admitted to hospital for glucose management were randomized to either SAP (Medtronic MiniMed Paradigm 722 system) or MDI with blinded CGM (Medtronic MiniMed CGMS System Gold) for a 2-week period. Glycaemic targets were defined as three preprandial measurements between 80 and 130mg/dL (4.4 and 7.2mmol/L) and three 2-h postprandial measurements between 80 and 180mg/dL (4.4 and 10.0mmol/L) within the same day. RESULTS: When data from 81 patients (40 SAP, 41 MDI) were analysed, 21 patients using SAP therapy, compared with six using MDI therapy, achieved their glycaemic targets within 3 days, and their time to reach their glucose targets was significantly shorter (3.7+/-1.1 vs 6.3+/-3.1 days for MDI; P<0.001), while three MDI patients failed to reach glycaemic targets within 14 days. SAP vs MDI patients experienced significantly less hypoglycaemia [sensor glucose<50mg/dL (2.8mmol/L): 0.04% vs 0.32%, respectively; P<0.05] and significantly less hyperglycaemia [sensor glucose>180mg/dL (10mmol/L): 21.56% vs 35.03%, respectively; P<0.05]. CONCLUSION: SAP vs MDI therapy in hospitalized patients with T2DM significantly reduced the time required to achieve glycaemic targets, and such systems may be a cost-effective way to improve glucose control and reduce hospital stays in T2DM patients. CI - Copyright (c) 2017 Elsevier Masson SAS. All rights reserved. FAU - Gu, W AU - Gu W AD - Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, China. Electronic address: guweijun301@163.com. FAU - Liu, Y AU - Liu Y AD - The Second Hospital of Jilin University, No. 218, Ziqiang Street, Nanguan District, Changchun, Jilin Province, China. Electronic address: drliuyu@jlu.edu.cn. FAU - Chen, Y AU - Chen Y AD - Fu Wai Hospital CAMS & PUMC, 167 Beilishi Road, Xi Cheng District, Beijing, China. Electronic address: doc.yan@medmail.com.cn. FAU - Deng, W AU - Deng W AD - Beijing Jishuitan Hospital, No. 31, Xin Jie Kou Eastern Street, Western District, Beijing, China. Electronic address: dengwei95@163.com. FAU - Ran, X AU - Ran X AD - West China Hospital-Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan Province, China. Electronic address: ranxingwu@163.com. FAU - Chen, L AU - Chen L AD - Union Hospital Tongji Medical College, No. 1277, Jiefang Avenue, Wuhan, Hubei Province, China. Electronic address: cheria_chen@126.com. FAU - Zhu, D AU - Zhu D AD - Nanjing Drum Tower Hospital, Nanjing University Medical School, No. 321, Zhongshan, Nanjing, China. Electronic address: zhudalong@nju.edu.cn. FAU - Yang, J AU - Yang J AD - Beijing Tongren Hospital, Capital Medical University, No. 1, Dong Jiao Min Xiang, Eastern District, Beijing, China. Electronic address: jinkui.yang@gmail.com. FAU - Shin, J AU - Shin J AD - Medtronic, 18000 Devonshire Street, Northridge, CA 91325, United States. Electronic address: john.shin@medtronic.com. FAU - Lee, S W AU - Lee SW AD - Medtronic, 18000 Devonshire Street, Northridge, CA 91325, United States. Electronic address: scott.w.lee@medtronic.com. FAU - Cordero, T L AU - Cordero TL AD - Medtronic, 18000 Devonshire Street, Northridge, CA 91325, United States. Electronic address: toni.l.cordero@medtronic.com. FAU - Mu, Y AU - Mu Y AD - Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, China. Electronic address: muyiming@301hospital.com.cn. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20170221 PL - France TA - Diabetes Metab JT - Diabetes & metabolism JID - 9607599 RN - 0 (Blood Glucose) RN - 0 (Hypoglycemic Agents) RN - 0 (Insulin) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Blood Glucose MH - Blood Glucose Self-Monitoring MH - China MH - Diabetes Mellitus, Type 2/blood/*drug therapy MH - Drug Administration Schedule MH - Female MH - Humans MH - Hypoglycemic Agents/administration & dosage/*therapeutic use MH - Insulin/administration & dosage/*therapeutic use MH - Insulin Infusion Systems MH - Male MH - Middle Aged MH - Young Adult OTO - NOTNLM OT - Continuous glucose monitoring OT - Hospitalized OT - Multiple daily injections OT - Sensor-augmented pump OT - Short-term intensive insulin OT - Type 2 diabetes EDAT- 2017/02/27 06:00 MHDA- 2018/06/07 06:00 CRDT- 2017/02/26 06:00 PHST- 2016/09/09 00:00 [received] PHST- 2016/11/09 00:00 [revised] PHST- 2016/12/19 00:00 [accepted] PHST- 2017/02/27 06:00 [pubmed] PHST- 2018/06/07 06:00 [medline] PHST- 2017/02/26 06:00 [entrez] AID - S1262-3636(17)30001-0 [pii] AID - 10.1016/j.diabet.2016.12.009 [doi] PST - ppublish SO - Diabetes Metab. 2017 Sep;43(4):359-363. doi: 10.1016/j.diabet.2016.12.009. Epub 2017 Feb 21.